Skip to main content
Premium Trial:

Request an Annual Quote

Meridian Bioscience Submits C. Difficile MDx Test to FDA

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Meridian Bioscience has submitted a 510(k) application with the US Food and Drug Administration for its illumigene C. difficile molecular diagnostic test.

The illumigene C. difficile test detects and amplifies a pathogenic DNA region of all toxin-producing strains of Clostridium difficile. The test uses a stool sample and can provide results in less than an hour, said Meridian.

The test represents the first molecular diagnostic product for the Cincinnati-based firm, which makes diagnostic tests for gastrointestinal and upper respiratory infections, serology, parasitology, and fungal diseases. It is based on Meridian's loop amplification technology, which is isothermal, requires no costly capital equipment, and can therefore run in any size laboratory, the company said.

Meridian hopes to have the test on the market later this year.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.